BMS 644950

Drug Profile

BMS 644950

Alternative Names: BMS-644950

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihyperlipidaemics; Pyrimidines; Triazoles
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Hypercholesterolaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hypercholesterolaemia(In volunteers) in USA (PO)
  • 15 Apr 2008 Phase-I clinical trials in Hypercholesterolaemia in USA (PO)
  • 15 Apr 2008 Pharmacokinetics and pharmacodynamics data from phase I and preclinical trials in Hypercholesterolaemia released by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top